Jonathan Miller
Stock Analyst at Evercore ISI
(1.15)
# 3,807
Out of 5,058 analysts
58
Total ratings
46.3%
Success rate
-1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Reiterated: Buy | $48 → $44 | $24.77 | +77.63% | 4 | Sep 29, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $4 | $1.24 | +222.58% | 3 | Sep 1, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $76 | $50.22 | +51.33% | 3 | Aug 31, 2026 | |
| ARVN Arvinas | Rated: Buy | $19 → $14 | $6.82 | +105.28% | 4 | Aug 10, 2026 | |
| NTLA Intellia Therapeutics | Upgraded: Buy | $16 → $24 | $11.43 | +109.97% | 6 | Aug 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $23 | $12.20 | +88.52% | 5 | Jul 20, 2026 | |
| EDIT Editas Medicine | Reiterated: Buy | $15 | $2.27 | +560.79% | 3 | May 27, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $9 | $2.03 | +343.35% | 1 | May 18, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $23 → $22 | $17.13 | +28.43% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $25 | $4.55 | +449.45% | 2 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $24 | $14.70 | +63.27% | 2 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $15 | $6.17 | +143.11% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 → $13 | $0.4601 | +2,725.47% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $22.53 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.25 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $4.62 | +29.87% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $11.18 | n/a | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $5.33 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.31 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.47 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.56 | n/a | 2 | May 5, 2021 |
Zymeworks
Sep 29, 2026
Reiterated: Buy
Price Target: $48 → $44
Current: $24.77
Upside: +77.63%
PMV Pharmaceuticals
Sep 1, 2026
Reiterated: Buy
Price Target: $4
Current: $1.24
Upside: +222.58%
CRISPR Therapeutics AG
Aug 31, 2026
Reiterated: Buy
Price Target: $76
Current: $50.22
Upside: +51.33%
Arvinas
Aug 10, 2026
Rated: Buy
Price Target: $19 → $14
Current: $6.82
Upside: +105.28%
Intellia Therapeutics
Aug 7, 2026
Upgraded: Buy
Price Target: $16 → $24
Current: $11.43
Upside: +109.97%
4D Molecular Therapeutics
Jul 20, 2026
Reiterated: Buy
Price Target: $23
Current: $12.20
Upside: +88.52%
Editas Medicine
May 27, 2026
Reiterated: Buy
Price Target: $15
Current: $2.27
Upside: +560.79%
Nkarta
May 18, 2026
Reiterated: Buy
Price Target: $9
Current: $2.03
Upside: +343.35%
Janux Therapeutics
May 11, 2026
Reiterated: Buy
Price Target: $23 → $22
Current: $17.13
Upside: +28.43%
Entrada Therapeutics
May 5, 2026
Reiterated: Buy
Price Target: $25
Current: $4.55
Upside: +449.45%
Apr 28, 2026
Reiterated: Buy
Price Target: $11 → $24
Current: $14.70
Upside: +63.27%
Apr 13, 2026
Reiterated: Buy
Price Target: $13 → $15
Current: $6.17
Upside: +143.11%
Mar 9, 2026
Reiterated: Buy
Price Target: $1 → $13
Current: $0.4601
Upside: +2,725.47%
Mar 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $22.53
Upside: -
Jan 26, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.25
Upside: -
Nov 28, 2025
Reiterated: Buy
Price Target: $6
Current: $4.62
Upside: +29.87%
Sep 30, 2025
Reiterated: Buy
Price Target: $12
Current: $11.18
Upside: n/a
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $5.33
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: n/a
Current: $3.31
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.47
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $9.56
Upside: n/a